[Ser140]-Myelin Proteolipid Protein (139-151) (depalmitoylated), human, bovine, dog, mouse, rat CAS NO.122018-58-0

The mechanism of action involves this peptide serving as an antigenic epitope that can be presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells to T-cells. The serine substitution at position 140 (replacing the natural palmitoylated cysteine) and de-palmitoylation modify the peptide's structure and potentially its immunogenicity compared to the native PLP sequence. When administered to susceptible animal models, this peptide can induce T-cell activation and proliferation, leading to an autoimmune response against myelin components. This T-cell-mediated immune response can result in inflammation, demyelination, and neurological symptoms characteristic of experimental autoimmune encephalomyelitis (EAE), making this peptide a tool for studying the immunopathogenesis of demyelinating diseases.

This PLP peptide analog is indicated for research use only in preclinical studies investigating autoimmune demyelinating diseases, neuroimmunology, and T-cell-mediated autoimmunity. It serves as an immunogenic peptide for inducing experimental autoimmune encephalomyelitis (EAE) in various animal models (mouse, rat, etc.) to study the pathogenesis of multiple sclerosis-like diseases. The product is used in T-cell proliferation assays, cytokine profiling studies, and investigations of immune tolerance mechanisms. The availability of species-specific variants (human, bovine, dog, mouse, rat) makes it particularly valuable for comparative immunology studies, cross-species reactivity assessments, and translational research. It is not intended for diagnostic, therapeutic, or clinical applications in humans or animals.

As a research reagent, [Ser140]-Myelin Proteolipid Protein (139-151) (depalmitoylated) does not have established clinical efficacy for therapeutic use in human patients. This peptide analog is used exclusively as an experimental tool to induce autoimmune disease in animal models for research purposes. It has not undergone clinical development or received regulatory approval for any medical indication. While studies using this peptide have contributed to the understanding of autoimmune demyelinating diseases and potential therapeutic targets, the product itself has no proven clinical efficacy or safety profile for human use. It is intended solely for laboratory research applications in appropriate scientific settings and should not be used in clinical contexts.